Abstract |
The purpose of this meta-analysis was to detect the association between the cholesteryl ester transfer protein gene polymorphisms and the risk of Alzheimer's disease (AD), carotid atherosclerosis, longevity, and the efficacy of statin therapy. Databases of MEDLINE, EMBASE, BIOSIS, the Cochrane Library, and the Chinese National Knowledge Infrastructure were systematically searched. Thirty-two studies were included in this meta-analysis. There was no difference in the I405V, C629A, and Taq1B polymorphisms between AD and control groups. However, stratified analysis showed that AD group had higher B2B2 genotype frequency than control group in Asian populations with APOE4+ in Taq1B. I405V and Taq1B polymorphisms were not associated with the risk of carotid atherosclerosis and longevity. The efficacy of statin therapy was not associated with Taq1B polymorphism. In conclusion, there was no association between cholesteryl ester transfer protein gene polymorphisms and the risk of AD, carotid atherosclerosis, longevity, and the efficacy of statin therapy in the pooled effects of overall population. However, the B2B2 genotype of Taq1B was associated with increased risk of AD in the Asian populations with APOE4+.
|
Authors | Qing Li, Ping Huang, Qian-Chao He, Quan-Zhen Lin, Jian Wu, Rui-Xing Yin |
Journal | Neurobiology of aging
(Neurobiol Aging)
Vol. 35
Issue 6
Pg. 1513.e13-23
(Jun 2014)
ISSN: 1558-1497 [Electronic] United States |
PMID | 24468472
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Inc. All rights reserved. |
Chemical References |
- Apolipoprotein E4
- CETP protein, human
- Cholesterol Ester Transfer Proteins
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Topics |
- Aged
- Aged, 80 and over
- Alzheimer Disease
(genetics)
- Apolipoprotein E4
- Asian People
- Carotid Artery Diseases
(genetics)
- Cholesterol Ester Transfer Proteins
(genetics)
- Databases, Bibliographic
- Female
- Genetic Association Studies
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Longevity
(genetics)
- Male
- Middle Aged
- Polymorphism, Genetic
(genetics)
- Risk
|